Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients

被引：27

作者：

Ashida, Atsuko ^{[1
]}

Sakaizawa, Kaori ^{[1
]}

Uhara, Hisashi ^{[1
]}

Okuyama, Ryuhei ^{[1
]}

机构：

[1] Shinshu Univ, Sch Med, Dept Dermatol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan

来源：

ACTA DERMATO-VENEREOLOGICA | 2017年 / 97卷 / 10期

关键词：

melanoma; circulating tumour DNA; anti-programmed cell death-1 antibody; BRAF; NRAS; droplet digital PCR; METASTATIC MELANOMA; NRAS MUTATIONS; DIGITAL PCR; BRAF; CANCER; RESISTANCE; NIVOLUMAB; THERAPY; UTILITY; PLASMA;

D O I：

10.2340/00015555-2748

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAF(mutant) or NRAS(mutant)) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2-4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.

引用

页码：1212 / 1218

页数：7

共 24 条

[1] Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR [J].

Ashida, Atsuko ;

Sakaizawa, Kaori ;

Mikoshiba, Asuka ;

Uhara, Hisashi ;

Okuyama, Ryuhei .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (05) :981-988

[2] Assessment of BRAF and KIT mutations in Japanese melanoma patients [J].

Ashida, Atsuko ;

Uhara, Hisashi ;

Kiniwa, Yukiko ;

Oguchi, Misae ;

Murata, Hiroshi ;

Goto, Yasufumi ;

Uchiyama, Aya ;

Ogawa, Eisaku ;

Hayashi, Koichi ;

Koga, Hiroshi ;

Okuyama, Ryuhei .

JOURNAL OF DERMATOLOGICAL SCIENCE, 2012, 66 (03) :240-242

[3] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[4] Distinct sets of genetic alterations in melanoma [J].

Curtin, JA ;

Fridlyand, J ;

Kageshita, T ;

Patel, HN ;

Busam, KJ ;

Kutzner, H ;

Cho, KH ;

Aiba, S ;

Bröcker, EB ;

LeBoit, PE ;

Pinkel, D ;

Bastian, BC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147

[5] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].

Diem, S. ;

Kasenda, B. ;

Spain, L. ;

Martin-Liberal, J. ;

Marconcini, R. ;

Gore, M. ;

Larkin, J. .

BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma [J].

Gray, Elin S. ;

Rizos, Helen ;

Reid, Anna L. ;

Boyd, Suzanah C. ;

Pereira, Michelle R. ;

Lo, Johnny ;

Tembe, Varsha ;

Freeman, James ;

Lee, Jenny H. J. ;

Scolyer, Richard A. ;

Siew, Kelvin ;

Lomma, Chris ;

Cooper, Adam ;

Khattak, Muhammad A. ;

Meniawy, Tarek M. ;

Long, Georgina V. ;

Carlino, Matteo S. ;

Millward, Michael ;

Ziman, Melanie .

ONCOTARGET, 2015, 6 (39) :42008-42018

[8] Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients [J].

Huang, Sharon K. ;

Hoon, Dave S. B. .

MOLECULAR ONCOLOGY, 2016, 10 (03) :450-463

[9] NRAS mutation status is an independent prognostic factor in metastatic melanoma [J].

Jakob, John A. ;

Bassett, Roland L., Jr. ;

Ng, Chaan S. ;

Curry, Jonathan L. ;

Joseph, Richard W. ;

Alvarado, Gladys C. ;

Rohlfs, Michelle L. ;

Richard, Jessie ;

Gershenwald, Jeffrey E. ;

Kim, Kevin B. ;

Lazar, Alexander J. ;

Hwu, Patrick ;

Davies, Michael A. .

CANCER, 2012, 118 (16) :4014-4023

[10] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade [J].

Lipson, Evan J. ;

Velculescu, Victor E. ;

Pritchard, Theresa S. ;

Sausen, Mark ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Diaz, Luis A., Jr. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2

← 1 2 3 →